Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Lung Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 36 articles: HTML format Text format

Single Articles

May 2018
1. HAN Z, Xiao Y, Wang K, Yan J, et al
   Development of a Novel SPECT Tracer to Image c-Met Expression in Non-Small Cell Lung Cancer in a Human Tumor Xenograft.
   J Nucl Med. 2018 May 18. pii: jnumed.117.206730. doi: 10.2967/jnumed.117.206730.
   PubMed     Text format     Abstract available
   
   
   April 2018
2. MCHUGH C, Thipparthi MR, Lawhorn-Crews JM, Polin L, et al
   Utilizing radiolabeled 3'-deoxy-3'-[(18)F]fluorothymidine with positron emission tomography to monitor the effect of dexamethasone on non-small cell lung cancer.
   J Nucl Med. 2018 Apr 19. pii: jnumed.117.207258. doi: 10.2967/jnumed.117.207258.
   PubMed     Text format     Abstract available
   
   
   November 2017
3. OLIN A, Ladefoged CN, Langer NH, Keller SH, et al
   Reproducibility of MR-based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer.
   J Nucl Med. 2017 Nov 9. pii: jnumed.117.198853. doi: 10.2967/jnumed.117.198853.
   PubMed     Text format     Abstract available
   
   
   June 2017
4. KRAMER GM, Frings V, Heijtel D, Smit EF, et al
   Parametric Method Performance for Dynamic 3'-Deoxy-3'-18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy.
   J Nucl Med. 2017;58:920-925.
   PubMed     Text format     Abstract available
   
   
   May 2017
5. FLEDELIUS J, Winther-Larsen A, Khalil AA, Bylov CM, et al
   18F-FDG-PET/CT for very early response evaluation predicts CT response in Erlotinib treated NSCLC patients - A comparison of assessment methods.
   J Nucl Med. 2017 May 10. pii: jnumed.117.193003. doi: 10.2967/jnumed.117.193003.
   PubMed     Text format     Abstract available
   
   
   
6. STEIGER S, Arvanitakis M, Sick B, Weder W, et al
   Analysis of prognostic values of various PET metrics in preoperative FDG PET for early stage bronchial carcinoma for progression free and overall survival: significantly increased glycolysis is a predictive factor.
   J Nucl Med. 2017 May 10. pii: jnumed.117.189894. doi: 10.2967/jnumed.117.189894.
   PubMed     Text format     Abstract available
   
   
   April 2017
7. MORBELLI S, Alama A, Ferrarazzo G, Coco S, et al
   Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): an 18F-FDG PET/CT study.
   J Nucl Med. 2017 Apr 27. pii: jnumed.117.193201. doi: 10.2967/jnumed.117.193201.
   PubMed     Text format     Abstract available
   
   
   March 2017
8. WARNDERS FJ, Terwisscha van Scheltinga AG, Knuehl C, van Roy M, et al
   HER3 specific biodistribution and tumor uptake of 89Zr-MSB0010853 visualized by real-time and non-invasive PET imaging.
   J Nucl Med. 2017 Mar 30. pii: jnumed.116.181586. doi: 10.2967/jnumed.116.181586.
   PubMed     Text format     Abstract available
   
   
   
9. USMANIJ EA, Natroshvili T, Timmer-Bonte JN, Oyen WJ, et al
   The predictive value of early in-treatment FDG-PET/CT response to chemotherapy in combination with bevacizumab in advanced non-squamous non-small cell lung cancer.
   J Nucl Med. 2017 Mar 23. pii: jnumed.116.185314. doi: 10.2967/jnumed.116.185314.
   PubMed     Text format     Abstract available
   
   
   
10. VERA P, Thureau S, Chaumet-Riffaud P, Modzelewski R, et al
    Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by F-miso PET/CT in patients with non-small cell lung carcinoma [RTEP5 study].
    J Nucl Med. 2017 Mar 2. pii: jnumed.116.188367. doi: 10.2967/jnumed.116.188367.
    PubMed     Text format     Abstract available
    
    
    February 2017
11. SCHWARTZ J, Grkovski M, Rimner A, Schoder H, et al
    Pharmacokinetic Analysis of Dynamic 18F-FMISO PET Data in Non-small Cell Lung Cancer.
    J Nucl Med. 2017 Feb 23. pii: jnumed.116.180422. doi: 10.2967/jnumed.116.180422.
    PubMed     Text format     Abstract available
    
    
    January 2017
12. HEKMAN MC, Rijpkema M, Bos D, Oosterwijk E, et al
    Detection of micrometastases using SPECT/fluorescence dual-modality imaging in a CEA-expressing tumor model.
    J Nucl Med. 2017 Jan 26. pii: jnumed.116.185470. doi: 10.2967/jnumed.116.185470.
    PubMed     Text format     Abstract available
    
    
    December 2016
13. NOTNI J, Reich D, Maltsev OV, Kapp TG, et al
    In-vivo PET imaging of the "cancer integrin" alphavbeta6 using gallium-68 labelled cyclic RGD nonapeptides.
    J Nucl Med. 2016 Dec 15. pii: jnumed.116.182824.
    PubMed     Text format     Abstract available
    
    
    October 2016
14. VALTORTA S, Moro M, Prisinzano G, Bertolini G, et al
    Metabolic evaluation of non-small cell lung cancer patient-derived xenografts models using [18F]FDG PET: potential tools for early therapy response.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.176404.
    PubMed     Text format     Abstract available
    
    
    
15. DESSEROIT MC, Tixier F, Weber WA, Siegel BA, et al
    Reliability of PET/CT shape and heterogeneity features in functional and morphological components of Non-Small Cell Lung Cancer tumors: a repeatability analysis in a prospective multi-center cohort.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.180919.
    PubMed     Text format     Abstract available
    
    
    
16. FAYAD H, Schmidt H, Kuestner T, Visvikis D, et al
    4D MR and attenuation map generation in PET/MR imaging using 4D PET derived deformation matrices: a feasibility study for lung cancer applications.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.178947.
    PubMed     Text format     Abstract available
    
    
    September 2016
17. SCHAEFFERKOETTER JD, Yan J, Soderlund TA, Townsend DW, et al
    Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.177592.
    PubMed     Text format     Abstract available
    
    
    
18. YIP SS, Kim J, Coroller T, Parmar C, et al
    Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.181826.
    PubMed     Text format     Abstract available
    
    
    June 2016
19. GROOTJANS W, Tixier F, van der Vos CS, Vriens D, et al
    The impact of optimal respiratory gating and image noise on evaluation of intra-tumor heterogeneity in 18F-FDG positron emission tomography imaging of lung cancer.
    J Nucl Med. 2016 Jun 9. pii: jnumed.116.173112.
    PubMed     Text format     Abstract available
    
    
    May 2016
20. CYSOUW MC, Kramer GM, Hoekstra OS, Frings V, et al
    Accuracy and precision of partial volume correction in oncological PET/CT studies.
    J Nucl Med. 2016 May 26. pii: jnumed.116.173831.
    PubMed     Text format     Abstract available
    
    
    April 2016
21. KRAMER GM, Frings V, Hoetjes N, Hoekstra OS, et al
    Repeatability of Quantitative Whole Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2016 Apr 21. pii: jnumed.115.170225.
    PubMed     Text format     Abstract available
    
    
    March 2016
22. TIXIER F, Vriens D, Cheze-Le Rest C, Hatt M, et al
    Comparison of tumor uptake heterogeneity characterization between static and parametric 18F-FDG PET images in Non-Small Cell Lung Cancer.
    J Nucl Med. 2016 Mar 10. pii: jnumed.115.166918.
    PubMed     Text format     Abstract available
    
    
    February 2016
23. OHRI N, Duan F, Snyder BS, Wei B, et al
    Pretreatment 18FDG-PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
    J Nucl Med. 2016 Feb 11. pii: jnumed.115.166934.
    PubMed     Text format     Abstract available
    
    
    
24. SHEIKHBAHAEI S, Mena E, Marcus C, Wray R, et al
    18F-Fluorodeoxyglucose PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.165480.
    PubMed     Text format     Abstract available
    
    
    January 2016
25. BURGER IA, Casanova R, Steiger S, Husmann L, et al
    FDG-PET/CT of non-small cell lung carcinoma under neo-adjuvant chemotherapy: background based adaptive volume metrics outperform TLG and MTV in predicting histopathological response.
    J Nucl Med. 2016 Jan 28. pii: jnumed.115.167684.
    PubMed     Text format     Abstract available
    
    
    
26. SAWICKI LM, Grueneisen J, Buchbender C, Schaarschmidt BM, et al
    Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT regarding detection and characterization of pulmonary lesions in 121 oncologic patients.
    J Nucl Med. 2016 Jan 7. pii: jnumed.115.167486.
    PubMed     Text format     Abstract available
    
    
    December 2015
27. KANG F, Wang S, Tian F, Zhao M, et al
    Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer (NSCLC) and Tuberculosis Patients.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.167924.
    PubMed     Text format     Abstract available
    
    
    
28. IQBAL R, Kramer GM, Verwer EE, Huisman MC, et al
    Multiparametric analysis of the relationship between tumor hypoxia and perfusion using 18F-FAZA and 15O-H2O PET.
    J Nucl Med. 2015 Dec 10. pii: jnumed.115.166579.
    PubMed     Text format     Abstract available
    
    
    
29. PRIOR JO, Peguret N, Pomoni A, Pappon M, et al
    Reduction of Respiratory Motion during PET/CT by Pulsatile-Flow Ventilation (PFV-PET/CT): A First Clinical Evaluation.
    J Nucl Med. 2015 Dec 3. pii: jnumed.115.163386.
    PubMed     Text format     Abstract available
    
    
    November 2015
30. PYKA T, Weirich G, Einspieler I, Maurer T, et al
    [68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.164442.
    PubMed     Text format     Abstract available
    
    
    
31. LAFFON E, Burger IA, Lamare F, de Clermont-Gallerande H, et al
    SUVpeak performance in Lung Cancer: Comparison to Average SUV from 40 Hottest Voxels.
    J Nucl Med. 2015 Nov 12. pii: jnumed.115.161968.
    PubMed     Text format     Abstract available
    
    
    October 2015
32. SAWICKI LM, Grueneisen J, Buchbender C, Schaarschmidt BM, et al
    Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared to 18F-FDG PET/CT in patients with known malignancies.
    J Nucl Med. 2015 Oct 29. pii: jnumed.115.162966.
    PubMed     Text format     Abstract available
    
    
    
33. HUELLNER MW, Barbosa FG, Husmann L, Pietsch CM, et al
    TNM staging of NSCLC: Comparison of PET/MR and PET/CT.
    J Nucl Med. 2015 Oct 15. pii: jnumed.115.162040.
    PubMed     Text format     Abstract available
    
    
    
34. WEBER WA, Gatsonis C, Siegel B
    Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
    J Nucl Med. 2015;56:1636.
    PubMed     Text format    
    
    
    
35. VAN DEN HOFF J, Hofheinz F
    Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
    J Nucl Med. 2015;56:1635-6.
    PubMed     Text format    
    
    
    September 2015
36. VAN DER VOS CS, Grootjans W, Osborne DR, Meeuwis AP, et al
    Improving the spatial alignment in PET/CT using amplitude-based respiratory gated PET and respiratory triggered CT.
    J Nucl Med. 2015 Sep 17. pii: jnumed.115.163055.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: